Digital Therapeutics in India: Are They Regulated as Medical Devices?
Digital therapeutics are software-based interventions meant to actually treat or manage a medical condition, not just track it, ranging from structured cognitive behavioural therapy apps for insomnia to software that guides diabetes management or post-stroke rehabilitation. For years, Indian regulation offered no clear answer on where these products fit. That changed with CDSCO’s finalised guidance on Medical Device Software in 2026, which names digital therapeutics explicitly for the first time.
What Counts as a Digital Therapeutic
The distinguishing feature of a digital therapeutic, compared with a general wellness or lifestyle app, is that it is intended to deliver a therapeutic intervention with a measurable clinical outcome, often as a standalone treatment or alongside medication, rather than simply logging symptoms or reminding a patient to take a pill. Apps offering structured therapy protocols for conditions such as insomnia, anxiety, substance dependence, or diabetes self-management typically fall into this category when they make a specific therapeutic claim.
This is different from a general fitness tracker or a symptom diary, which does not claim to treat a condition and therefore usually stays outside medical device regulation altogether.
CDSCO’s 2026 Guidance Brings Digital Therapeutics Into Scope
CDSCO’s finalised Medical Device Software guidance, building on an October 2025 draft, expressly extends its scope to software using artificial intelligence, Internet of Things connectivity, digital therapeutics, and advanced data analytics when intended for a medical purpose. General wellness, fitness, and administrative software remain outside the guidance’s reach, but a digital therapeutic making a treatment claim is treated the same way as any other Software as a Medical Device.
This places digital therapeutics under the same risk-based classification structure used for other software medical devices, meaning a product’s class depends on the severity of the condition it addresses and how significant its output is to a clinical decision. A digital therapeutic used to manage a life-threatening condition or one that directly drives a treatment decision without physician review would be expected to sit at a higher risk class than one offering supportive, clinician-supervised guidance.
Compliance Obligations for Developers
Once a digital therapeutic is classified as a medical device, its developer needs to build and document a quality management system aligned with recognised standards such as IEC 62304 for software lifecycle processes and ISO 14971 for risk management, register the product through the SUGAM portal, and obtain a licence appropriate to its risk class from either a state licensing authority or CDSCO’s central licensing authority.
The 2026 guidance also introduces expectations around cybersecurity, a documented software bill of materials, and continued post-market performance monitoring once the product is in clinical use. For a startup building a therapeutic app, this is a materially different compliance burden than shipping a consumer wellness product, and it needs to be planned for from the design stage rather than retrofitted after launch.
What This Means for Clinics Recommending These Apps
Clinics and individual doctors recommending a digital therapeutic to patients should ask the developer whether the product has been classified and licensed under CDSCO’s framework, particularly where the app is positioned as a treatment rather than a support tool. Prescribing or recommending an unregistered product that makes a therapeutic claim could expose both the clinic and the patient to avoidable risk if the software’s clinical claims have not been independently assessed.
For patients with chronic conditions where a digital therapeutic is used alongside standard care, documenting that the recommended app is CDSCO-compliant is a reasonable addition to informed consent discussions, especially as more insurers and hospital systems begin formally integrating these tools into treatment pathways.
Conclusion
Digital therapeutics have moved from an unregulated grey area to an explicitly named category under India’s medical device software framework. Developers building these products, and clinicians recommending them, both benefit from treating CDSCO classification as a starting checkpoint rather than an afterthought.
Researched Resources
1. CDSCO Final Guidance for Medical Device Software (MDSW) 2026
2. India Medical Device Software Regulation 2026
3. CDSCO Medical Device Registration in India: What’s Changed in 2026
4. Medical Device Regulation India: CDSCO Guide 2026
Disclaimer: This article is for general informational and educational purposes and reflects CDSCO’s Medical Device Software guidance on digital therapeutics as understood at the time of writing; classification thresholds and licensing procedures continue to evolve. It is not regulatory or legal advice, and developers and clinics should confirm specific product classification directly with CDSCO or a qualified regulatory consultant.
Vivek Chaudhary is a Technical Content Developer specializing in healthcare, health technology, and digital healthcare business solutions. He creates research-driven, SEO-focused content for doctors, clinics, hospitals, healthcare professionals, and patients, covering topics such as healthcare technology, patient engagement, clinic management, digital communication, and online visibility.
